ODI Pharma AB (“ODI” or the “Company”) today announces a reverse profit warning following a significantly strong revenue development for the period October–December 2025 (Q2).   Preliminary and unaudited figures indicate that ODI achieved revenues of approximately SEK 11 million during the second quarter 2025/2026. This corresponds to an increase of approximately 84.3 percent compared to Q1 2025/2026 and a substantial increase compared to the corresponding quarter of the prev

Idag den 5 december 2025 hölls årsstämma i ODI Pharma AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet.   Fastställande av resultaträkning och balansräkning Årsstämman beslutade att fastställa den framlagda resultaträkningen och balansräkningen samt koncernresultaträkningen och koncernbalansräkningen. Dispositioner beträffande bolagets resultat enligt den fastställda balansräkningen Årsstämman beslutade at

Today, the 5 th  of December 2025, ODI Pharma AB (publ) held its Annual General Meeting ("AGM"). Below is a summary of the decisions made. All decisions were made with the required majority.   Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet. Allocation of the company's profit or loss The AGM resolved to dispose of the compa

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2025 - September 2025. The report is available as an attached document to this press release and on the Company's website ( www.odipharma.com ). Below is a summary of the report.   First quarter (2025-07-01 – 2025-09-30) ·        The Group's net sales amounted to SEK 5,968,143 (143,793). ·        The Group's profit after financial items amounted to SEK -37,027 (-1,468,183). ·       

ODI Pharma AB (“ODI Pharma” or the “Company”) provides an operational update following recent improvements in its commercial performance. Strategic and practical measures implemented in recent quarters have begun to show clear results, supported by a more stable regulatory environment and smoother product flows into the Polish market.   ODI Pharma’s commercial activity has strengthened in recent months as earlier operational and strategic measures begin to take effect. The Co

The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal year 2024/2025. The annual report, along with the accompanying auditor’s report, is available as an attached file and on the websites of ODI Pharma ( www.odipharma.com ) and Spotlight Stock Market ( www.spotlightstockmarket.com ).   The auditor has made the following observation:   Material uncertainty relating to going concern Without quali

Styrelsen och verkställande direktören för ODI Pharma AB ("ODI Pharma") publicerar härmed årsredovisningen för räkenskapsåret 2024/2025. Årsredovisningen, tillsammans med revisionsberättelsen, finns tillgänglig som en bifogad fil och på ODI Pharmas ( www.odipharma.com ) och Spotlight Stock Markets ( www.spotlightstockmarket.com ) respektive hemsidor.   Revisorn har gjort följande anmärkning: Väsentlig osäkerhetsfaktor avseende antagandet om fortsatt drift Utan att det påverka

The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Friday, 5th of December 2025, at 15:00 at the company's premises at Östermalmstorg 1, 114 42 Stockholm.   Right to participate and registration Shareholders who wish to attend the Annual General Meeting shall ·        be included in the Euroclear Sweden AB share no later than the 27th of November 2025, and ·        sign up to the company no later than the 1st of D

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma fredagen den 5 december 2025 kl. 15:00 i bolagets lokaler på Östermalmstorg 1, 114 42 i Stockholm.   Rätt att delta och anmälan Aktieägare som önskar delta i bolagsstämman ska ·        vara införd i den av Euroclear Sweden AB förda aktieboken den 27 november 2025, och  ·        anmäla sig till bolaget senast den 1 december 2025 skriftligen per e-post till info@odipharma.com . I anmälan bör uppges fu

ODI Pharma AB (“ODI” or the “Company”) hereby publishes the financial calendar for the 2025/2026 fiscal year. ODI’s updated financial...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2024 - June 2025. The report is available...

Today, 26 June 2025, an Extraordinary General Meeting was held in ODI Pharma AB (publ), reg. no. 559223-1392. Below is a summary of the...

Idag, den 26 juni 2025, hölls en extra bolagsstämma i ODI Pharma AB (publ), org.nr 559223-1392. Nedan följer en sammanfattning av de...

Aktieägarna i ODI Pharma AB (publ), 559223-1392, kallas härmed till extra bolagsstämma torsdagen den 26 juni 2025 kl. 14.30 i bolagets...

The shareholders of ODI Pharma AB (publ), 559223-1392, are hereby invited to an Extraordinary General Meeting to be held on Thursday 26...

The Board of Directors of ODI Pharma AB (publ) (“ODI Pharma” or the “Company”) has resolved to propose a directed share issue of...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2024 - March 2025. The report is available...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July 2024 – December 2024. The report is...

ODI Pharma AB ("ODI Pharma") hereby informs the termination of the agreement regarding the liquidity provider with Pareto Securities AB....

Today, the 30th of December 2024, ODI Pharma AB (publ) held its Annual General Meeting (“AGM”). A summary of the resolutions follows...